What is Ajanta Pharma share?
Ajanta Pharma share represents ownership in Ajanta Pharma Limited, a listed speciality-pharma company on the NSE and BSE (ticker: AJANTPHARM, BSE code: 532331). The company operates in branded generics in India and emerging markets, plus generics in the US, giving it a diversified and relatively resilient revenue model.
Basic stock snapshot (as of early 2026)
- Current share price: around ₹2,900–₹2,920.
- Market capitalisation: roughly ₹36,400–₹36,500 crore.
- Sector: Pharmaceuticals & Drugs.
- Listing: NSE and BSE.
Ajanta Pharma share sits comfortably in the mid‑cap zone—large enough to be liquid, but small enough to still have a growth runway, which many long‑term investors find attractive. It feels similar to the kind of “quality mid‑cap pharma” story that tends to do well when earnings are consistent and the balance sheet is clean.
Business model and what Ajanta Pharma does
Ajanta Pharma is not a mass‑market, low‑margin generic manufacturer; it is a speciality-pharma company that targets specific therapeutic areas where it can command better pricing and differentiation. This focus is exactly why many analysts and investors keep an eye on Ajanta Pharma share rather than treating it like a generic “pharma index” stock.
Key business segments
- Branded generics in India
Ajanta sells branded formulations across cardiology, ophthalmology, dermatology, pain management, nephrology, and gynaecology in India. These are not just plain generics; many are first‑to‑market or differentiated products that doctors prefer over cheaper, undifferentiated options. - Emerging markets (ROW)
The company exports to over 30 countries in Asia, Africa, and other emerging regions. In these markets, Ajanta offers a mix of antimalarials, cardiovascular, gastrointestinal, antibiotic, dermatology, antihistamine, multivitamin, gynaecology, and pain‑management products. - US generics
In the US, Ajanta operates in the generic space, supplying products that are approved by the US FDA. This segment is more price‑sensitive, but it benefits from the company’s strong manufacturing and regulatory track record. - Institutional and contract business
Ajanta also does institutional sales in Africa and contract manufacturing for other global pharma companies. This diversifies revenue and helps utilise its manufacturing capacity more efficiently.
How many plants and where are they?
Ajanta Pharma runs a network of 7 state‑of‑the‑art manufacturing facilities, mostly in India, with some presence in Mauritius. Out of these, 6 plants manufacture finished formulations, and 1 plant focuses on Active Pharmaceutical Ingredients (APIs), largely for captive consumption.
Two of the Indian facilities, Paithan (Maharashtra) and Dahej (Gujarat), are approved by the US FDA, which is a big plus for export‑oriented pharma companies. FDA‑approved plants mean stricter quality norms, fewer regulatory risks, and better chances of winning US‑generic tenders, which in turn supports the long‑term thesis behind Ajanta Pharma share.
Famous products and medicines
Ajanta Pharma’s product basket has over 500 products, with roughly half being first‑to‑market or differentiated offerings. This is a key reason why the company can maintain better margins than typical commodity‑generic players.
Ophthalmology
Ajanta enjoys a strong position in eye‑care in India and is ranked around 2nd in ophthalmology by IQVIA data. Popular products include:
- Bimat (anti‑glaucoma)
- Nepaflam (anti‑inflammatory)
- Softdrops (lubricant)
- Olopat and Alcarex (anti‑allergics)
Cardiology
In cardiology, Ajanta has launched innovative formulations such as:
- MET XL (extended‑release Metoprolol)
- Atorfit CV (Atorvastatin + Clopidogrel)
- Cinod (Cilnidipine for hypertension)
- Rosutor Gold (triple combo: Aspirin + Rosuvastatin + Clopidogrel)
- Dapalex (SGLT2 inhibitor)
- Vilatin (DDDP4 inhibitor)
Nephrology and gynaecology
Ajanta has expanded into nephrology, covering pre‑dialysis, dialysis, and transplant‑related needs with products like:
In gynaecology, the company offers brands such as:
Ajanta Pharma share price and valuation
As of early 2026, Ajanta Pharma share trades around ₹2,900–₹2,920, giving it a market cap of roughly ₹36,400–₹36,500 crore.
Key valuation and financial metrics (simplified)
Is Ajanta Pharma debt free?
Ajanta Pharma share is whether the company is debt free. The answer, in simple terms, is yes, effectively debt free on the long‑term side.
Read Also: Afcons Infrastructure Share Future Outlook, Promoter Holding & Risks (2026)
Debt and balance‑sheet strength
- As of March 2025, Ajanta Pharma had zero long‑term debt and a net cash position, reflected in a negative net debt‑to‑equity ratio of about –0.16.
- Shareholder funds stood at around ₹3,790 crore, up from ₹3,567 crore the previous year, showing healthy profit retention.
Earlier research also notes that the company’s capital expenditure of about ₹1,650 crore was funded entirely from internal accruals, again highlighting a debt‑free, cash‑rich model. For your readers, this is a strong positive: Ajanta Pharma share is backed by a clean balance sheet, which reduces financial risk and gives management flexibility to invest in R&D or acquisitions without raising fresh debt.
Who is the CEO and the leadership of Ajanta Pharma?
Key leadership names
- Managing Director (MD): Mr. Yogesh Agrawal – He is widely seen as the driving force behind Ajanta’s corporate turnaround and its rise as a leading branded‑generic player from India. Under his leadership, the company strengthened its research, manufacturing, and international footprint.
- Joint Managing Director (JMD): Mr. Rajesh Agrawal – He has played a major role in transforming Ajanta’s India business and expanding into new therapeutic areas like gynaecology and nephrology.
- Chairman: Mr. Mannalal Agrawal – He provides strategic guidance and governance oversight, drawing on decades of business experience.
Who is the owner of Ajanta Pharma?
The “owner” of Ajanta Pharma is essentially the promoter group, which holds a majority stake in the company.
Promoter holding and key entities
In 2022, promoter entities sold about 4.3% stake for roughly ₹637 crore, indicating some partial monetisation while still retaining control. For your readers, this means Ajanta Pharma share is promoter‑owned but not overly concentrated, and the family‑run setup can be both a strength (long‑term vision) and a risk (governance scrutiny).
Ajanta Pharma competitors
Ajanta Pharma share is complete without a quick look at its competitive landscape. The company competes with both Indian and global players in its chosen therapeutic segments.
Key competitor types
- Indian specialty‑pharma peers
- Sun Pharma, Dr. Reddy’s, Lupin, Glenmark, Alkem, Cipla, etc., all have strong presence in cardiology, dermatology, and ophthalmology.
- Ajanta differentiates by focusing on niche, first‑to‑market products rather than broad‑spectrum generics.
- US‑generic players
- In the US, Ajanta faces competition from companies like Mylan (Viatris), Teva, Aurobindo, and other generic manufacturers.
- Here, the battle is on price, scale, and regulatory approvals, which is why FDA‑approved plants matter so much.
- Regional and emerging‑market players
- In Asia and Africa, Ajanta competes with local pharma firms and other Indian exporters.
- Its diversified revenue across geographies helps it offset slowdowns in any single region.
Why investors track Ajanta Pharma share
Why Ajanta Pharma share keeps appearing in investor discussions:
- Niche, high‑growth segments: Cardiology, ophthalmology, dermatology, pain management, nephrology, and gynaecology are all areas with strong demand and pricing power.
- First‑to‑market strategy: Around half the product basket is first‑to‑market, which supports better margins and brand recall.
- Clean balance sheet: Zero long‑term debt and a net cash position reduce financial risk.
- Promoter‑led, aligned management: Family‑run but with professional governance, which many long‑term investors like.
- Diversified revenue: India branded generics, emerging markets, US generics, and institutional sales spread risk across geographies and channels.
Key risks around Ajanta Pharma share
- Valuation sensitivity: At a P/E of around 36x, the stock is not cheap; any earnings miss or margin pressure can trigger sharp corrections.
- Regulatory risk in the US: Any adverse FDA findings at its plants can impact US‑generic approvals and revenues.
- Competition in key segments: Cardiology and ophthalmology are crowded; if peers launch cheaper or better‑differentiated products, Ajanta’s pricing power can weaken.
- Currency and export risk: A large part of revenue comes from exports; rupee‑dollar fluctuations can affect margins and reported earnings.
How to think about Ajanta Pharma share in your portfolio
- If you are a long‑term, growth‑oriented investor: Ajanta Pharma share can fit as a mid‑cap pharma allocation, especially if you already have core holdings in large‑cap index funds or blue‑chip stocks.
- If you are more conservative: The premium valuation and sector‑specific risks mean it may not be suitable as a large single‑stock bet; better to keep position size small and diversified.
- If you are a trader or swing investor: The stock can be volatile around results, FDA updates, or broader pharma‑sector news, so risk management (stop‑loss, position sizing) becomes critical.
FAQ – about Ajanta Pharma share
Is Ajanta Pharma debt free?
Yes, Ajanta Pharma has zero long‑term debt and a net cash position as of March 2025, with a negative net debt‑to‑equity ratio of about –0.16. This means the company is effectively debt free on the long‑term side and financially strong.
Who is the CEO of Ajanta Pharma?
The Managing Director (MD) of Ajanta Pharma is Mr. Yogesh Agrawal, who is widely regarded as the key driver behind the company’s turnaround and growth. The Joint Managing Director is Mr. Rajesh Agrawal, and Mr. Mannalal Agrawal serves as Chairman.
Who is the owner of Ajanta Pharma?
The promoter group, led by the Agrawal family, owns about 66.2% of Ajanta Pharma. Key promoter entities include Yogesh M. Agrawal, Rajesh M. Agrawal, Ravi P. Agrawal, Aayush M. Agrawal, and their respective trusts, along with Gabs Investments Private Limited and Ganga Exports.
What are the famous products of Ajanta Pharma?
Ajanta Pharma’s famous products span several therapeutic areas:
- Ophthalmology: Bimat, Nepaflam, Softdrops, Olopat, Alcarex.
- Cardiology: MET XL, Atorfit CV, Cinod, Rosutor Gold, Dapalex, Vilatin.
- Nephrology: Renagold DS, Dabanox, Fumac, Tocyl, Phenolac S, Valpose.
- Gynaecology: Amgest, Apcor, Caltuf, Dagiran, Fedate, Menoroz, Poliquin, Spazio.
How many plants are there in Ajanta Pharma?
Ajanta Pharma operates 7 state‑of‑the‑art manufacturing facilities, mostly in India, with one plant dedicated to APIs and six to finished formulations. Two of its Indian plants (Paithan and Dahej) are approved by the US FDA.
What are the famous medicines of Ajanta Pharma?
The famous medicines of Ajanta Pharma include the brands listed above under ophthalmology, cardiology, nephrology, and gynaecology. These are often first‑to‑market or differentiated products that give the company an edge in pricing and market share.
Who are the promoters of Ajanta Pharma?
The main promoters of Ajanta Pharma are Yogesh M. Agrawal, Rajesh M. Agrawal, Ravi P. Agrawal, Aayush M. Agrawal, along with their respective trusts, Gabs Investments Private Limited, and Ganga Exports. Together, they hold around 66.2% of the company.
What are Ajanta Pharma competitors?
Ajanta Pharma competes with Indian speciality-pharma companies like Sun Pharma, Dr. Reddy’s, Lupin, Glenmark, Cipla, and Alkem, as well as global and regional generic players in the US and emerging markets. Its niche-focused strategy helps differentiate it from broader‑based generic manufacturers.
Disclaimer
The above content is for informational and educational purposes only and should not be considered as investment advice. Please consult a qualified financial advisor before making any investment decisions.
